Authors
Michelle Chen, Nadya Pyatigorskaya, Marc Benayoun, Maria Rosana Ponisio, Vilma Kosovic, Ana M Franceschi
Published in
Neuroimaging clinics of North America. Volume 37. Issue 1. Pages 233-247. Epub Sep 29, 2026.
Abstract
Neurotheranostics integrates diagnostic PET imaging with targeted radioligand therapy to enable molecularly guided treatment of central nervous system malignancies. Validated and emerging theranostic targets include somatostatin receptor subtype 2 for meningiomas, prostate-specific membrane antigen and L-type amino acid transporter 1 for gliomas, and fibroblast activation protein, chemokine receptor-4, and gastrin-releasing peptide receptor as investigational candidates. Alpha particle therapy through NK-1 receptor targeting addresses key resistance mechanisms in glioblastoma. For each target, diagnostic imaging characteristics, therapeutic applications, and interpretive considerations are presented. Translational barriers including dosimetric challenges, infrastructure requirements, and the need for standardized response criteria are evaluated.
PMID:
43014983
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0